Obesity affects over a third of the global population and is a major risk factor for numerous chronic diseases. To find ...

Heme oxygenase 1 (HO-1) has an influential yet insufficiently investigated effect on Sirtuin 1 (SIRT1), a histone deacetylase ...

A study by the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) reveals that inflammation ...

BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ...

A panelist discusses how axatilimab, a humanized IgG4 monoclonal antibody targeting CSF-1 receptors on monocytes and macrophages, showed promising results in the AGAVE-201 trial for ...

STENOVA is a randomized, double-blind, placebo-controlled study in 103 patients with symptomatic FSCD. Patients are randomized to receive one of two doses of AGMB-129 (200mg twice-daily or 100mg ...

Innovative antisense therapy blocking production of TGF-β2 shows promise in reducing retinal fibrosis and improving outcomes ...

A study reveals that inflammation associated with Marfan syndrome increases vulnerability to neurological diseases and complications following strokes, as demonstrated in animal models.

Unresolved Treatment Needs in IPF. Idiopathic Pulmonary Fibrosis (IPF) is a progressive, irreversible, and fatal interstitial lung disease characterized ...

A new study published in Engineering has identified enolase 2 (ENO2) as a key factor in the lymphatic metastasis of head and neck squamous cell ...

Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced multiple ...